Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion (Nasdaq: BMEA), a clinical stage biopharmaceutical company targeting metabolic diseases and genetically defined cancers, announced a grant of non-qualified stock options to a new employee. This grant, approved by the compensation committee on August 1, 2024, allows the purchase of 7,500 shares of Biomea's common stock. The stock options will vest quarterly over four years, contingent upon the employee's continued employment. These options were awarded under the Biomea 2023 Inducement Equity Plan, adhering to Nasdaq Listing Rule 5635(c)(4), and were a material inducement for the employee's hiring.
Biomea Fusion (Nasdaq: BMEA), un'azienda biofarmaceutica in fase clinica che si concentra su malattie metaboliche e tumori geneticamente definiti, ha annunciato l'attribuzione di opzioni su azioni non qualificate a un nuovo dipendente. Questa concessione, approvata dal comitato per le compensazioni il 1 agosto 2024, consente l'acquisto di 7.500 azioni ordinarie di Biomea. Le opzioni su azioni matureranno trimestralmente per quattro anni, a condizione del mantenimento dell'impiego del dipendente. Queste opzioni sono state conferite nell'ambito del Piano di Induzione Azionaria Biomea 2023, in conformità con la Regola di Listing Nasdaq 5635(c)(4), e sono state un incentivo significativo per l'assunzione del dipendente.
Biomea Fusion (Nasdaq: BMEA), una empresa biofarmacéutica en etapa clínica que se centra en enfermedades metabólicas y cánceres genéticamente definidos, anunció la concesión de opciones sobre acciones no calificadas a un nuevo empleado. Esta concesión, aprobada por el comité de compensación el 1 de agosto de 2024, permite la compra de 7,500 acciones ordinarias de Biomea. Las opciones sobre acciones se otorgarán trimestralmente durante cuatro años, dependiendo de la continuación del empleo del empleado. Estas opciones fueron otorgadas bajo el Plan de Inducción de Capital Biomea 2023, de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4), y fueron un incentivo material para la contratación del empleado.
Biomea Fusion (Nasdaq: BMEA)는 대사 질환과 유전자에 의해 정의된 암을 대상으로 하는 임상 단계의 바이오 의약품 회사로, 새로운 직원에게 비인정 주식 옵션을 부여한다고 발표했습니다. 이 부여는 2024년 8월 1일 보상 위원회의 승인 아래 이루어지며, Biomea의 보통주 7,500주를 구매할 수 있습니다. 이 주식 옵션은 직원의 지속적인 고용을 조건으로 4년간 분기별로 발생합니다. 이러한 옵션은 Biomea 2023 유도 증권 계획에 따라 수여되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수하며, 직원의 채용을 위한 주요 유인으로 작용했습니다.
Biomea Fusion (Nasdaq: BMEA), une entreprise biopharmaceutique en phase clinique ciblant les maladies métaboliques et les cancers génétiquement définis, a annoncé l'octroi d'options d'achat d'actions non qualifiées à un nouvel employé. Cette attribution, approuvée par le comité de rémunération le 1er août 2024, permet l'achat de 7 500 actions ordinaires de Biomea. Les options sur actions acquériront des droits trimestriellement sur quatre ans, sous réserve que l'employé demeure en poste. Ces options ont été accordées dans le cadre du Plan d'Induction en Capital 2023 de Biomea, conformément à la Règle de Cotation Nasdaq 5635(c)(4), et ont constitué un encouragement essentiel à l'embauche de l'employé.
Biomea Fusion (Nasdaq: BMEA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Stoffwechselerkrankungen und genetisch definierte Krebsarten spezialisiert hat, gab die Gewährung von nicht qualifizierten Aktienoptionen an einen neuen Mitarbeiter bekannt. Diese Gewährung, die am 1. August 2024 vom Vergütungsausschuss genehmigt wurde, ermöglicht den Kauf von 7.500 Stammaktien von Biomea. Die Aktienoptionen werden vierteljährlich über einen Zeitraum von vier Jahren fällig, abhängig von der fortgesetzten Beschäftigung des Mitarbeiters. Diese Optionen wurden im Rahmen des Biomea 2023 Induktions-Aktienplans gewährt, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4), und waren ein wesentlicher Anreiz für die Einstellung des Mitarbeiters.
- None.
- Grant of stock options might lead to potential dilution of shares if the employee exercises stock options.
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with metabolic diseases and genetically defined cancers, today announced that on August 1, 2024, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 7,500 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook.
FAQ
What did Biomea Fusion announce on August 1, 2024?
What is the ticker symbol for Biomea Fusion?
Under which plan were the stock options granted?
How will the stock options granted to the new employee vest?
Why were the stock options granted to the new employee?
